Lana Janes

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Abdera Therapeutics, Inc. is a Canadian precision oncology company that operates in the field of cancer treatment. The CEO of the company is Lana Elizabeth Janes.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Abdera Therapeutics, Inc. is a Canadian precision oncology company that operates in the field of cancer treatment. The CEO of the company is Lana Elizabeth Janes.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Abdera Therapeutics, Inc. is a Canadian precision oncology company that operates in the field of cancer treatment. The CEO of the company is Lana Elizabeth Janes.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada.

Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada.